TY - JOUR
T1 - Principles of adoptive T cell therapy in cancer
AU - Met, Özcan
AU - Jensen, Kasper Mølgaard
AU - Chamberlain, Christopher Aled
AU - Donia, Marco
AU - Svane, Inge Marie
PY - 2019/1/11
Y1 - 2019/1/11
N2 - Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.
AB - Adoptive cell therapy (ACT) utilizing either tumor-infiltrating lymphocyte (TIL)-derived T cells or T cells genetically engineered to express tumor recognizing receptors has emerged as a powerful and potentially curative therapy for several cancers. Many ACT-based therapies have recently entered late-phase clinical testing, with several T cell therapies already achieving regulatory approval for the treatment of patients with B cell malignancies. In this review, we briefly outline the principles of adoptively transferred T cells for the treatment of cancer.
KW - Adoptive cell therapy
KW - Cancer immunotherapy
KW - Chimeric antigen receptor
KW - T cells
KW - Tumor-infiltrating lymphocytes
U2 - 10.1007/s00281-018-0703-z
DO - 10.1007/s00281-018-0703-z
M3 - Journal article
C2 - 30187086
AN - SCOPUS:85053396565
SN - 1863-2297
VL - 41
SP - 49
EP - 58
JO - Seminars in Immunopathology
JF - Seminars in Immunopathology
IS - 1
ER -
